The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups.
Gat I, Shlush E, Quach K, Librach CL.
Syst Biol Reprod Med. 2015;61(6):336-44. doi: 10.3109/19396368.2015.1089607. Epub 2015 Oct 30.
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A, Zhang C, Austria T, Li YJ, Huang R, Lugo Santiago N, Kohut A, Zhao Q, Borrero RM, Shen B, Cristea M, Wang EW, Song M, Rodriguez-Rodriguez L, Yu H.
J Immunother Cancer. 2024 Apr 5;12(4):e007716. doi: 10.1136/jitc-2023-007716.
The normal menstrual cycle in women.
Mihm M, Gangooly S, Muttukrishna S.
Anim Reprod Sci. 2011 Apr;124(3-4):229-36. doi: 10.1016/j.anireprosci.2010.08.030. Epub 2010 Sep 3.
Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.
Cavarzerani E, Caligiuri I, Bartoletti M, Corona G, Perin T, Palumbo A, Ditto A, Occhiali T, Canzonieri V, Rizzolio F.
J Adv Res. 2026 May;83:379-390. doi: 10.1016/j.jare.2025.08.009. Epub 2025 Aug 7.
New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
Torkildsen CF, Austdal M, Jarmund AH, Kleinmanns K, Lamark EK, Nilsen EB, Stefansson I, Sande RK, Iversen AC, Thomsen LCV, Bjørge L.
Front Immunol. 2024 Jun 14;15:1394497. doi: 10.3389/fimmu.2024.1394497. eCollection 2024.
Patient-derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin.
Zhao Y, Wang C, Deng W, Li L, Liu J, Shi Y, Tao X, Zhang J, Cao Q, Cai C, Han X.
MedComm (2020). 2024 Aug 28;5(9):e697. doi: 10.1002/mco2.697. eCollection 2024 Sep.
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine.
Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G.
Gynecol Oncol Rep. 2020 Feb 13;32:100547. doi: 10.1016/j.gore.2020.100547. eCollection 2020 May.
The best ovarian reserve marker to predict ovarian response following controlled ovarian hyperstimulation: a systematic review and meta-analysis.
Salemi F, Jambarsang S, Kheirkhah A, Salehi-Abargouei A, Ahmadnia Z, Hosseini HA, Lotfi M, Amer S.
Syst Rev. 2024 Dec 18;13(1):303. doi: 10.1186/s13643-024-02684-0.
Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites.
Zhang C, Wang Y, He M, Wang C, Cao K, Zhong Y, Wang X, Yang M, Zhang G, Lu J, Yi H, Liu H, Xu C.
Cancer Res. 2025 Jul 2;85(13):2468-2484. doi: 10.1158/0008-5472.CAN-24-3209.
Pathological response of ovarian cancer to neoadjuvant chemotherapy.
Ivantsov AO.
Chin Clin Oncol. 2018 Dec;7(6):59. doi: 10.21037/cco.2018.09.07.
